New therapies for hepatic fibrosis
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is an outcome of many chronic diseases, and often results in cirrhosis, liver failure, and portal hypertension. Liver transplantation is the only treatment available for patients with advanced stages of liver cirrhosis. Therefore, alternative methods are required to develop new strategies for anti-fibrotic therapy. Various kinds of hepatocyte injuries cause inflammatory reactions which lead to activation of hepatic stellate cells (HSCs). Continuous liver injuries maintain these activated HSCs, and they are called as myofibroblasts. Myofibroblasts proliferate in response to various kinds of cytokines and produce extracellular matrix proteins (ECMs). Myofibroblasts undergo apoptosis and inactivation when the underlying causative etiologies are cleared. Here we describe the current knowledge of targeting the activated HSCs as a therapeutic target for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Self-citationMorris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090353 · Cited by 487
Murphy, F. R., Issa, R., Zhou, X., Ratnarajah, S., Arthur, M. J. P., Benyon, C., Iredale, J. P., & Nagase, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111490200 · Cited by 432
Reduction of Bleomycin-Induced Pulmonary Fibrosis by Serum Amyloid P
Pilling, D., Roife, D., Wang, M., Ronkainen, S. D., Crawford, J. R., Travis, E. L., & Gomer, R. H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.6.4035 · Cited by 230
Role of αvβ6 integrin in acute biliary fibrosis
Wang, B., Dolinski, B. M., Kikuchi, N., Leone, D. R., Peters, M. G., Weinreb, P. H., Violette, S. M., & Bissell, M. D. (2007) · Hepatology · doi:10.1002/hep.21849 · Cited by 163
Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist
Iwaisako, K., Haimerl, M., Paik, Y.-H., Taura, K., Kodama, Y., Sirlin, C., Yu, E., Yu, R. T., Downes, M., Evans, R. M., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202464109 · Cited by 157
Self-citationRegulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells
Fadok, V. A., McDonald, P. P., Bratton, D. L., & Henson, P. M. (1998) · Biochemical Society Transactions · doi:10.1042/bst0260653 · Cited by 134
Cited by
Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X. (2022) · Science Advances · doi:10.1126/sciadv.abp9435 · Cited by 299
Hepatic fibrosis: It is time to go with hepatic stellate cell-specific therapeutic targets
Ezhilarasan, D., Sokal, E., & Najimi, M. (2018) · Hepatobiliary & Pancreatic Diseases International · doi:10.1016/j.hbpd.2018.04.003 · Cited by 204
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease
Jump, D. B., Lytle, K. A., Depner, C. M., & Tripathy, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.007 · Cited by 142
Sojoodi, M., Erstad, D. J., Barrett, S. C., Salloum, S., Zhu, S., Qian, T., Colon, S., Gale, E. M., Jordan, V. C., Wang, Y., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.01.015 · Cited by 35
“Strategies to promote resolution of fibrosis include the induction of apoptosis by myofibroblasts, inhibition of collagen cross-linking, and triggering degrading and clearance of ECM.52 In this study, we identified a hepatic microenvironment with moderately elevated levels of ROS, in which hepatic macrophages digest c…”
BackgroundInfluential
Metadata
- Authors
- Koyama, Y., & Brenner, D. A.
- Venue
- Clinics and Research in Hepatology and Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 39
- Pages
- S75-S79
- ISSN
- 2210-7401 (ISSN-L)
- OpenAlex
- W1927146021
- Cited by
- 37
- References
- 7
- FWCI
- 2.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: New therapies for hepatic fibrosis. https://app.cochat.ai/papers/10.1016/j.clinre.2015.06.011
- The paper
- Koyama, Y., & Brenner, D. A. (2015). New therapies for hepatic fibrosis. Clinics and Research in Hepatology and Gastroenterology. https://doi.org/10.1016/j.clinre.2015.06.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.